Esperion Therapeutics | ESPR - Passifs Courants





Passifs Courants Changement Date
AbbVie USD 43.29B 3.9B 2025-12
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Alterity Therapeutics Limited AUD 1.73M 2.77M 2025-12
Amarin USD 179.64M 14.82M 2026-03
Amgen USD 24.96B 534M 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Cipla INR 62.97B 8.13B 2025-09
CSL USD 4.61B 207M 2025-12
Cytokinetics USD 199.18M 3.27M 2026-03
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Esperion Therapeutics USD 300.81M 58.22M 2025-12
Geron USD 113.82M 26.11M 2025-12
Grifols EUR 2.37B 156.97M 2025-12
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Heron Therapeutics USD 96.1M 6.39M 2025-12
Ionis Pharmaceuticals USD 717M 66M 2026-03
Merck USD 26.94B 1.38B 2026-03
Minerva Neurosciences USD 2.29M 381K 2025-12
Moderna USD 2.4B 408M 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 968.43M 102.18M 2025-12
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Sanofi EUR 30.01B 1.66B 2026-03
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
United Therapeutics USD 560.6M 14.3M 2025-12
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12